SLAMF7-directed Immunostimulatory Antibody [EPC]

5171 reported adverse events

Drugs of this class: ELOTUZUMAB

These side effects are most commonly reported by patients taking drugs of the SLAMF7-directed Immunostimulatory Antibody [EPC] class:

# Side effect Count
0 PLASMA CELL MYELOMA 576
1 PNEUMONIA 304
2 DEATH 298
3 MALIGNANT NEOPLASM PROGRESSION 254
4 FATIGUE 236
5 DIARRHOEA 231
6 PYREXIA 221
7 DRUG INEFFECTIVE 204
8 NEUTROPENIA 194
9 ANAEMIA 173
See all common reactions for SLAMF7-directed Immunostimulatory Antibody [EPC]

Drugs of the SLAMF7-directed Immunostimulatory Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PARAINFLUENZAE VIRAL LARYNGOTRACHEOBRONCHITIS 2 0.6667
1 HUMAN METAPNEUMOVIRUS TEST 3 0.5000
2 ANORECTAL HUMAN PAPILLOMA VIRUS INFECTION 3 0.1000
3 ANTIVIRAL PROPHYLAXIS 1 0.0909
4 BLADDER TRANSITIONAL CELL CARCINOMA STAGE 0 2 0.0769
5 FACTOR VII DEFICIENCY 5 0.0746
6 RESPIROVIRUS TEST POSITIVE 5 0.0735
7 BENCE JONES PROTEIN URINE PRESENT 1 0.0357
8 PARAPROTEINAEMIA 11 0.0355
9 PLASMA CELL MYELOMA REFRACTORY 47 0.0351
See all enriched reactions for SLAMF7-directed Immunostimulatory Antibody [EPC]